Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Financial Flexibility Index
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Financial Flexibility Index of -2.82x as of March 2026. Free cash flow of $-3.00 Million (operating CF $-3.00 Million minus capex $3.00) represents -3% of total liabilities ($1.06 Million). Also explore net asset growth rate of Cadrenal Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cadrenal Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for Cadrenal Therapeutics, Inc. Common Stock across 4 annual periods. Check CVKD PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Cadrenal Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year free cash flow to debt coverage for Cadrenal Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Cadrenal Therapeutics, Inc. Common Stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -7.93x | $-12.60 Million | $-12.60 Million | $1.59 Million | ▼ -189.6% |
| 2024 | -2.74x | $-7.35 Million | $-7.36 Million | $2.68 Million | ▲ +35.8% |
| 2023 | -4.27x | $-3.53 Million | $-3.53 Million | $826.88K | ▼ -2145.6% |
| 2022 | -0.19x | $-1.20 Million | $-1.20 Million | $6.33 Million | — |